IGF-1 LR3

IGF-1 LR3 is an 83-amino-acid analogue of human IGF-1 with an N-terminal 13-amino-acid extension and a Glu→Arg substitution at position 3. These modifications dramatically reduce binding to IGF binding proteins (IGFBPs), extending plasma half-life from ~15 minutes to 20–30 hours. IGF-1 signals through IGF-1R and secondarily IR to activate PI3K/AKT and MAPK/ERK pathways, driving protein synthesis, glucose uptake, cell proliferation, and anti-apoptotic signaling.

Myosatellite cells: Key research on muscle fiber repair, hypertrophy, and hyperplasia in in vitro and animal models.

Protein synthesis: Consistent upregulation of mTOR pathway markers in skeletal muscle tissue research.

Neuroprotection: IGF-1 receptor signaling extensively studied in neuronal survival and differentiation models.

Bone: Positive effects on osteoblast activity and bone mineral density in animal models.

IGFBP independence: The LR3 modification dramatically increases bioavailability vs unmodified IGF-1.